Posted by Michael Wonder on 10 Feb 2018
Grifols HyperRAB (rabies immune globulin [human]) 300 IU/mL receives FDA approval to treat patients exposed to rabies virus infection
6 February 2018 - Reduced volume of medication offers potential for fewer injections for patients.
Grifols has received approval from the U.S. FDA for a new higher potency formulation of its HyperRAB rabies immune globulin [human] for rabies post-exposure prophylaxis (treatment of a person immediately after exposure to the rabies virus).
The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options, offering a greater concentration of anti-rabies virus antibodies within each mL of volume, and for patients, the potential for fewer injections by significantly reducing the volume of medication administered in each dose.
